Sangamo Therapeutics, Inc. Stock News
$0.53
1.51%
Nasdaq,
Jul 03, 10:50 pm CET
Sangamo Therapeutics, Inc. Stock News
Neutral
Business Wire
●
12 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.
Neutral
Seeking Alpha
●
about 2 months ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist L...
Neutral
Business Wire
●
about 2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.
Neutral
Business Wire
●
about 2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.
Neutral
Business Wire
●
about 2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS POSTPONES FIRST QUARTER 2025 CONFERENCE CALL TO LATER THE SAME DAY.
Neutral
Business Wire
●
2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.
Neutral
Business Wire
●
2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease.
Neutral
Business Wire
●
2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT).
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
